Stent. Relieve. Revive: EVT Rewrites the Story of Post-Thrombotic Syndrome 🩺⚡

A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome?   The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate–severe disease—measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit is clinically meaningful.   But every intervention casts a shadow.   👉 Bleeding risk was ~3-fold higher, largely driven by intensified antithrombotic therapy. 👉 Durability beyond 6 months remains unknown.   This is not a simple "yes or no" trial—it is a study in nuance, trade-offs, and patient-centered decision making.   For the right patient—severe symptoms, clear iliac obstruction, acceptable bleeding risk—EVT may offer a path from limitation to liberation.   The vein opens. The patient breathes. The clinician pauses.   Science advances not in absolutes—but in balance. ⚖️🩺